This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
With the rise of AI technologies, we could see significant advancements in cancer treatment, making it more efficient and potentially leading to a cure. By analyzing vast amounts of data from medical records, laboratory tests and imaging scans, AI algorithms can provide a more precise diagnosis, which can lead to better treatment outcomes.
DTC ads do NOT lead to unnecessary Rxs. 3hree: DTC marketing minimizes the sideeffects of prescription drugs – One of the top pages within prescription drug websites continues to be “safety information.” 4our: DTC marketing should be illegal because it leads to unnecessary Rx’s.
While patients have the right to full disclosure, misinformation and scare tactics could lead to more deaths from COVID. The major concerns for hesitancy included worries over sideeffects and that the vaccine is too new. Also cited was a lack of trust in the government to ensure the vaccines’ safety and effectiveness.
A new approach to potassium-channel openers for epilepsy Critically, XEN1101 combines the effectiveness of potassium-channel openers with the safety of more traditional drugs, stated study lead author and neurologist Dr Jacqueline French. After a year or more, about 11 percent had no seizures.
One leading proponent of the approach – South San Francisco’s Nkarta – has just reported new results from an early-stage trial of one of its CAR-NK therapies that will likely add to the enthusiasm for the field. There are still questions about the durability of the effects however, as NK cells have a limited lifespan within the body.
For people with [propionic acidaemia], harmful amounts of toxic metabolites can build up in the body and lead to metabolic decompensation events and multisystemic complications. I am particularly proud of these results given that there are currently no therapeutic treatments approved for patients with this disease,” Dr Holen explained.
billion buyout of Principia Biopharma has run into trouble, after the FDA placed it on partial clinical hold while a safety signal is investigated. Those changes haven’t been enough to prevent the FDA from taking action, although outside the US the studies will continue as planned with the tighter safety monitoring.
This interchangeability refers to the fact that a reference medicine can be substituted by a biosimilar, without risk, sideeffects or outcomes different to the original drug. Analytical evidence by the EMA indicated that there was a lack of safety concerns regarding approval of biosimilars compared with their reference medicines.
If the orally-delivered drug is confirmed have similar in safety and efficiency as the injectable forms, researchers stated that a PCSK9 inhibitor in a pill form could lower costs, increase convenience and expand patient access to the treatment. This is a highly effective compound that was well tolerated,” stated Dr Christie M.
Saphnelo is also being studied in a Phase III trial in lupus nephritis, where a person’s immune system targets the kidneys, eventually leading to kidney failure. The CAR-T therapies for conditions like lupus continue to look promising, but their safety is a concern, says Gilkeson.
Treatment-related sideeffects included nausea and headache but were generally mild. “As As an oncologist for many years, I experienced the frustration of not being able to provide cancer care that treats the whole person, not just the tumour,” commented Manish Agrawal, MD, of Sunstone Therapies and lead author of the study.
The deal includes Karuna’s lead asset KarXT (xanomeline-trospium), a potential first-in-class treatment for schizophrenia. KarXT targets both the M1 and M4 muscarinic receptors, resulting in a differentiated safety and efficacy profile.
New results from a first-of-its-kind study reports that a CAR-T cell therapy provided similar efficacy and safety to relapsed or refractory multiple myeloma patients administered with the treatment in clinical trials.
The trial is designed to analyse the safety and efficacy of Hemgenix. The mean adjusted annualised bleeding rate (ABR) for all bleeds declined by 54% in the seven to 18 months following infusion versus the six-month lead-in period on factor IX prophylactic replacement therapy.
But how can pharma marketing teams maximize the impact of PPC campaigns while ensuring compliance and generating high-value leads? Include lead capture forms, whitepapers, or product demos for deeper engagement. Non-compliance can lead to penalties, reputation damage, and ad disapprovals.
Lead Generation: Drive patient education sign-ups, HCP event registrations, and drug sample requests. A single misstepsuch as targeting the wrong audience or omitting safety disclaimers can lead to regulatory violations and ad disapprovals. Brand Authority: Position your company as a trusted leader in therapeutic areas.
Ocular suspensions and emulsions can deliver hydrophobic drugs, but may lead to blurred vision. Elements leading to a rational design of cyclodextrin-based formulations … Turning to innovative technology Looking to innovative technology solutions, nanotechnology-based carriers are gaining popularity, the review suggested.
Speciality pharmacies play a crucial role in medication dosing, disease and sideeffects management, and patient care. Patient education and medication adverse effect counselling. Patient monitoring for safety and efficacy. The post Leading speciality pharmacies in pharma appeared first on Pharmaceutical Technology.
By incorporating a more comprehensive range of individuals in clinical trials, researchers can obtain valuable insights into the efficacy and safety of drugs across various populations. This can lead to faster access to information, reduce the need for large cohorts and therefore an acceleration in progress in medical research.
At week 28, the study assessed the vaccine’s safety and levels of anti-HBV surface antibodies (HBsAbs). The most common sideeffects related to vaccination were injection site pain, malaise, fatigue, muscle aches and headaches. The international study will continue to examine the effects of two-dose HEPLISAV-B.
Once prescribed the medication, you can include questions about weight loss and sideeffects to assess progress and make necessary adjustments. Improve Data Accuracy and Compliance Handwritten forms can lead to misinterpretations, incomplete fields, and errors impacting patient care and compliance with healthcare regulations.
Positively, Brager shared that in clinical trials , the company’s lead clinical candidate has demonstrated ability to cross the blood-brain barrier and to “not cause serious sideeffects common with traditional immunosuppressive therapies that treat inflammation.”
Content Marketing as a Sales Driver: Unlocking Your Business Potential in the Pharmaceutical Industry Content marketing is a long-term strategy that can help businesses of all sizes generate leads, increase brand awareness, and drive sales.
Clene has presented updated trial results for its Visionary MS Phase II clinical trial for its lead pipeline candidate, CNM-Au8. The Visionary trial has exclusively enrolled MS patients with chronic optic neuropathy, in which progression of MS leads to damage of the optic nerve. before the submission to the FDA.
NGN-401 showed robust therapeutic and safety benefits while delivering MECP2 to important regions of the brain that are affected by Rett syndrome in a comprehensive preclinical programme. The transgene regulation technology can be tuned to provide a desired transgene expression level in a narrow range.
This is different from clinical trials which are really designed to look at efficacy and safety in a very controlled environment, so controlled trials are very good at answering those two questions. They’re wonderful medications, blockbuster sales, but real sideeffects. Do they have any sideeffects associated with them?
Next, pharmacists review the participant’s genetic results – along with health data such as drug, lifestyle, and food interactions – to customize a “Medication Action Plan” that members’ physicians can access to determine which drugs should be prescribed to increase safety and efficacy.
In NASH, excess fat in the liver can lead to progressive disease, including inflammation, liver cell injury and fibrosis, which are associated with increased risk for cardiovascular disease and liver morbidity and mortality. Pegozafermin also has a favourable safety and tolerability profile, with few gastrointestinal (GI) sideeffects.
Panelists discuss how VMAT2 inhibitors' most commonly reported adverse effects include somnolence, fatigue, and mild parkinsonism symptoms, which can typically be managed through dose adjustments and careful titration strategies, while noting these sideeffects are generally less severe than those of older treatments and rarely lead to discontinuation (..)
Karuna Therapeutics has unveiled positive topline results from its phase 3 EMERGENT-2 trial evaluating the efficacy, safety, and tolerability of its lead investigational therapy, KarXT (xanomeline-trospium), in adults with schizophrenia.
This leads to the formation of immune complexes that deposit in the glomerulus and result in haematuria, proteinuria, and decline in kidney function. Individuals who receive corticosteroids may experience limited efficacy, alongside significant sideeffects. IgAN is the most common primary glomerulonephritis worldwide.
This leads to the formation of immune complexes that deposit in the glomerulus and result in haematuria, proteinuria, and decline in kidney function. Individuals who receive corticosteroids may experience limited efficacy, alongside significant sideeffects. IgAN is the most common primary glomerulonephritis worldwide.
New data on Sarepta’s gene therapy for Duchenne muscular dystrophy (DMD) has gone a long way towards building confidence in its efficacy – but have introduced a concern about its safety. In the case of Pfizer’s candidate, that clinical hold occurred after cases of myocarditis were seen that have been linked to the gene therapy.
A pharmacologist by training, Rawlins was the founding chairman of health technology assessment (HTA) agency NICE , leading the organisation from its inception in 1999 until 2013, and hired Sir Andrew Dillon to become the organisation’s founding chief executive.
The regulatory agency has determined that the NDA is a class 2 review , which leads to a six-month review period from the date of resubmission. Diarrhea was the most common sideeffect with XPHOZAH. It has set a user fee goal date of 17 October this year.
The company’s lead candidate, C21, is an angiotensin II type 2 receptor agonist (ATRAG). This data, together with a favourable safety profile, make C21 a potential game-changer for IPF patients, particularly those who are currently not treated due to the sideeffects of the available drugs, according to Dalsgaard.
Belgium-headquartered ANeuroTech is participating in a Series B round, which will raise up to $150m to power the pivotal programme of its lead candidate ANT01 for use as an adjunctive treatment for major depressive disorder (MDD). Due to this, adjunctive treatments are used as part of a patient’s treatment regimen.
However, due to conjugation instability and unfavorable safety profiles of currently available ADCs, we can still do more to ensure ADCs are more broadly available and amenable options for the patients who need them. What Other Developments Within Oncology Excite You? What Is Your Company Currently Working On?
Targeting toxic species of Abeta, such as multimers (with aducanumab and lecanemab) or pyroglutamate Abeta3-42 (with donanemab), induced significant removal of Abeta plaque load in the brains of Alzheimer’s patients, leading to the delay in cognitive decline. Treatment with the mAbs delayed cognitive decline by 2.6 months for lecanemab and 5.5
In theory, this will allow for highly tailored, personalized therapy plans with superior efficacy and minimal sideeffects. In turn, this can support decision-making and lead to more efficient inventory management and faster delivery times, enhance supply chain visibility and transparency, and avoid overproduction and waste.
GnRH antagonists have an improved safety and efficacy profile compared to the marketed GnRH agonists, which have significant sideeffects that are unappealing to patients. Kissei Pharmaceutical’s GnRH antagonist, Yselty (linzagolix), will be another important driver of growth during the forecast period.
Hard on the heels of a new $575 million partnership with GSK, US biotech SpringWorks Therapeutics has reported phase 3 data at ESMO that sets up regulatory filings for its lead drug nirogacestat in a rare and aggressive form of soft tissue cancer.
But before pharmaceutical companies can go to market with a breakthrough drug, they need to ensure safety and efficacy through clinical trials. Pharma companies need tools like AI that can reliably improve this percentage without jeopardizing safety. The need for new medical treatments and drugs has never been greater.
Payers must take into consideration not only the clinical efficacy of a drug, but also its safety profile, sideeffects, and cost-effectiveness, among other factors. The implementation of the resulting recommendations can reduce payer uncertainty and lead to optimized HTA submissions.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content